RxDoctor Payments Data

Stewart Miller, MD

Ophthalmology · Columbia, SCNPI 1871592824

Payments from drug & device makers

$945in general payments, 2019–2025

Across 48 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$172
  • AbbVie$140
  • Kala Pharmaceuticals, Inc.$123
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$116
  • Glaukos Corporation$86
  • Sun Pharmaceutical Industries Inc.$65
  • plus $243 from 8 others

What the payments were for

  • Food & beverage$945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$945 in reported general payments places this provider in the 30th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$154,320
Medicare patients
807
Services billed
1,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine47$52,458
LumiganBimatoprost76$33,581
Cyclosporine51$29,751
XiidraLifitegrast25$27,497
CombiganBrimonidine Tartrate/Timolol45$15,336
VyzultaLatanoprostene Bunod36$12,417
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol61$10,337
Latanoprost568$6,851
Timolol Maleate313$5,543
Alphagan PBrimonidine Tartrate14$4,259
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat178$4,095
Bromfenac Sodium14$2,268
Tobramycin-DexamethasoneTobramycin/Dexamethasone23$1,071
Prednisolone Acetate16$802
Brimonidine Tartrate94$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$140$105,635182 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$36$39,91461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →